$ASPI

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 . Regulation FD Disclosure. As previously disclosed, on June 25, 2026, ASP Isotopes Inc., a Delaware corporation (“ASPI” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporati

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 ASP Isotopes Hosts Inaugural Capital Markets Day and Provides Operational Update DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and process

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 14, 2026, Renergen Limited (the “Borrower”), a wholly-owned subsidiary of ASP Isotopes Inc. (the “Company”), entered into a Second Amendment and Restatement Agreement (the “Second Amendment”) with The Standard Bank o

ASP Isotopes (ASPI) presented at the Emerging Growth Conference, outlining plans to commercialize projects in helium, isotopes, and nuclear fuel. CEO Paul Mann highlighted execution risks and supply shortages. The stock is down 73% from its 52-week high. The company aims to generate revenue and free cash flow over the next six months, with Phase 2 of its South African helium and LNG project fully funded. PET Labs reported 50% revenue growth in H1 2024, with expectations to double in 2026. The co

ASP Isotopes Inc. (NASDAQ: ASPI) announced that its subsidiary Renergen's Tetra4 has started commissioning a liquid helium plant in South Africa. Phase 1 expects to produce 70 Mcf/day of helium and 2,500 GJ/day of LNG, with commercial production starting in Q3 2026. Annual revenues are projected at over $27 million. Phase 2, 13 times larger, may begin construction in 2H 2026.

Simply Wall St reports ASP Isotopes (ASPI) shares fell 0.2% to about $4.27 after earnings. Q2 2026 revenue rose to $5.123M from $1.198M, while net loss narrowed to $33.585M from $75.062M and basic EPS loss improved to $0.27 from $1.03. The article cites dilution from $109.2M of notes converted into about 23.2M shares.

ASPI Isotopes Inc. reported quarterly revenue of $5.1M, with growth attributed to acquisitions and new segment contributions. Net loss from continuing operations narrowed to $34.0M. The company completed its Renergen acquisition, expanded into helium and LNG, and improved liquidity, while citing integration, regulatory, and financing risks.

ASP Isotopes (ASPI) reported first-half 2026 revenue of $9.3M, up from $2.3M a year earlier, driven by specialist isotopes, new U.S. radiopharmacy operations, and helium and LNG activity tied to the Renergen acquisition, plus TerraPower collaboration revenue. Gross profit was $3.1M, but it posted a $60.7M loss from continuing operations and $40.0M operating cash outflow. Cash and short-term investments totaled $254.9M.

ASP Isotopes said Tetra4, a subsidiary of Renergen, signed a five-year take-or-pay LNG offtake for its Virginia Gas Project in South Africa. The deal covers about 10% of Phase 1 capacity, priced above $16 per GJ, and supports revenue certainty. Phase 1 targets ~2,500 GJ/day LNG and ~70 Mcf/day helium, with operations in Q3 2026; Phase 1 revenue could exceed $27M annually.

ASP Isotopes (ASPI) said group revenues are rising and three business units are nearing profitability inflection points ahead of its Q2 results. CEO Paul Mann cited PET Labs’ >50% organic revenue growth in H1 and forecast $14m full-year revenue (from $6m in 2025). ASPI reiterated its 2031 EBITDA target >$300m, with $330m to $700m expected, supported by long-term take-or-pay helium and LNG contracts via Renergen.